Translational Development Acquisition Corp.’s (NASDAQ:TDACU) Lock-Up Period Set To End Tomorrow

Translational Development Acquisition’s (NASDAQ:TDACUGet Free Report) lock-up period will expire on Monday, June 23rd. Translational Development Acquisition had issued 15,000,000 shares in its public offering on December 23rd. The total size of the offering was $150,000,000 based on an initial share price of $10.00. After the expiration of Translational Development Acquisition’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Translational Development Acquisition Price Performance

Shares of TDACU opened at $10.35 on Friday. Translational Development Acquisition has a 52 week low of $10.00 and a 52 week high of $10.42. The firm has a fifty day moving average price of $10.26.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Parallax Volatility Advisers L.P. bought a new position in Translational Development Acquisition during the 4th quarter worth $929,000. Wealthspring Capital LLC bought a new position in Translational Development Acquisition during the 4th quarter worth $1,095,000. Yakira Capital Management Inc. bought a new position in Translational Development Acquisition during the 4th quarter worth $1,106,000. Tabor Asset Management LP bought a new position in Translational Development Acquisition during the 1st quarter worth $1,106,000. Finally, Warberg Asset Management LLC bought a new position in Translational Development Acquisition during the 4th quarter worth $1,373,000.

About Translational Development Acquisition

(Get Free Report)

Trident Acquisitions Corp. does not have significant operations. It intends to enter into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more target businesses primarily in the oil and gas or other natural resource sector.

Featured Stories

Receive News & Ratings for Translational Development Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translational Development Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.